PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...
Polycythemia hyperviscosity syndrome has been associated with multiple systemic effects. There is dearth of data on the effects of polycythemia on cardiac function. This case presents a newborn infant ...
The FDA has approved Jakafi (ruxolitinib) as a treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, based on findings from the phase 3 RESPONSE trial. The Food ...
LIVER tumors, usually hepatomas, are relatively frequent in cases of hepatic cirrhosis, occurring in approximately 3 or 4 per cent of patients with alcoholic cirrhosis and in a somewhat higher ...
December 8, 2012 — Atlanta, GA — Maintaining a lower hematocrit (HCT) can help lower the risk for cardiovascular (CV) death in patients with polycythemia vera, according to the results of a new study.
Background A 16-year-old white male with a history of obstructive uropathy presented to a pediatric outpatient clinic with a first syncope. At presentation, he had a hemoglobin level of 220 g/l, a ...
Dear Dr. Donohue: I have just been diagnosed with polycythemia. I had a bone marrow test that showed my red blood cells are overproducing. Information on this condition would be appreciated. L.S. Dear ...
Dublin, Feb. 17, 2025 (GLOBE NEWSWIRE) -- The "Polycythemia Vera - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report ...
The investigators in a recent study found that prior thrombotic events and leukocytosis were linked to subsequent thrombotic events in general, and prior arterial events and hyperlipidemia were linked ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...
The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results